Svenda's Manual of OTC Stocks - My readers can get it at a $100-200 discount

Hello fellow investors,

Those of you that regularly follow my blog will know that I primarily focus on the Over the Counter (OTC) Markets in order to hunt for value where the least amount of competition exists.

The problem with the OTC markets is that there is no easy or quick way to screen for investment opportunities. One must manually work through the thousands of companies to uncover value. Thankfully a solution now exists which removes a lot of the hard work.

I recently came across the work of Jan Svenda who has been focusing on the OTC markets for a few years now. He has completed the Herculean task of going through every OTC stock one by one in order to uncover investment opportunities.

Having separated the wheat from the chaff he has compiled a digital manual, ‘Svenda’s Manual of OTC Stocks’, which contains a collection of the most interesting investment ideas in the OTC space.

I have personally purchased the full version of the manual and found it to be full of useful ideas and information. Whilst I enjoy the process of looking through stocks it is helpful to have a ready-made list of companies to look up with an idea of the company’s back story, business and approximate valuation.

Jan has kindly offered to provide readers of my blog with the opportunity to purchase his manual at a discount, considering the amount of work he has put into it I consider it to be a great value proposition.

I bought ‘Svenda’s Manual of OTC Stocks’ and am recommending it to my readers because I think it is a real bargain.

Over to Jan with the offer,

David

---

Dear readers,

I am excited to share an exclusive offer with you given David’s focus on OTC and microcaps. As some of you may know in the past 15 months I ran a newsletter exclusively focused on the OTC space.

Recently, I decided to compile all of the past research tied to the newsletter and offer it to investors.

I am offering two versions of my ‘Svenda’s Manual of OTC Stocks’.

• Abridged Version

This will give you access to 56 long ideas spanning 348 pages. On top of the 56 ideas, you will also get access to a report where I build a portfolio of 20 interesting community banks.

This version usually costs $299, but for you as a reader of Elementary Value, the price is $199. You can purchase this version here. Once you pay you will receive the PDF straight away. You can find a sample of the document here.

• Full Version

This will get you everything in the abridged version and you will also acquire a serious coverage of 351 meaningful stocks in the OTC land over 402 pages. Out of those 351 stocks, 25 are dark where I share information that can be hard to get.

This version usually costs $599, but for you as a reader of Elementary Value, the price is $399. You can purchase this version here. Once you pay you will receive the PDF straight away. You can find a sample of the document here.

Now, you might be wondering; ‘Are there any investment opportunities?’

Most certainly.

32 stocks out of the 56 long ideas still have not moved by more than 20% (up or down). The community bank portfolio is up only 4.85% so far. The latest report is from early October. Thus, the research is relevant and up to date.

The performance and volume analysis of the long ideas, also shows that the ideas are actionable for various portfolio sizes.

The second question that might pop in your head could be; ‘Okay, what is the use of the other research?’

It is a powerful reference point that you can use when doing your own research. Many OTC stocks have sparse public ‘coverage’. There might be some analysis from someone that is five years old. There might not be anything out there as is often the case.

Given the sheer amount of meaningful OTC stocks I researched, you are going to acquire a unique source of relevant information.

As I like to say, simply knowing about an OTC company will make sure you are halfway in discovering an investment opportunity.
 
These documents will allow you to achieve that and greatly reduce the risk of you missing out on the next OTC opportunity.

I will greatly appreciate any feedback.

Thanks,

Jan Svenda